Pacer Advisors Inc. increased its stake in Syneos Health Inc (NASDAQ:SYNH) by 8,256.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,233 shares of the company’s stock after acquiring an additional 23,943 shares during the period. Pacer Advisors Inc.’s holdings in Syneos Health were worth $1,238,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. ClariVest Asset Management LLC boosted its holdings in shares of Syneos Health by 267.9% in the first quarter. ClariVest Asset Management LLC now owns 174,541 shares of the company’s stock valued at $9,035,000 after acquiring an additional 127,098 shares in the last quarter. Boston Advisors LLC bought a new position in shares of Syneos Health in the second quarter valued at approximately $1,257,000. Geode Capital Management LLC boosted its holdings in shares of Syneos Health by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 738,567 shares of the company’s stock valued at $29,061,000 after acquiring an additional 50,175 shares in the last quarter. BB&T Corp boosted its holdings in shares of Syneos Health by 8.1% in the second quarter. BB&T Corp now owns 8,749 shares of the company’s stock valued at $448,000 after acquiring an additional 656 shares in the last quarter. Finally, AMI Asset Management Corp boosted its holdings in shares of Syneos Health by 42.8% in the second quarter. AMI Asset Management Corp now owns 355,755 shares of the company’s stock valued at $18,176,000 after acquiring an additional 106,594 shares in the last quarter.

SYNH stock traded up $0.26 on Friday, hitting $54.61. 7,643 shares of the company’s stock traded hands, compared to its average volume of 374,914. Syneos Health Inc has a 1-year low of $36.26 and a 1-year high of $56.34. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of 20.84, a P/E/G ratio of 1.81 and a beta of 1.51. The stock has a fifty day moving average of $51.06 and a 200-day moving average of $48.13. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 0.99.

Syneos Health (NASDAQ:SYNH) last released its earnings results on Tuesday, August 6th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.59 by $0.02. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Syneos Health had a net margin of 0.36% and a return on equity of 9.82%. The business’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.62 earnings per share. On average, equities research analysts anticipate that Syneos Health Inc will post 2.73 earnings per share for the current fiscal year.

Several analysts recently commented on the stock. Credit Suisse Group increased their target price on shares of Syneos Health from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Zacks Investment Research lowered shares of Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 target price for the company. in a research note on Tuesday. SunTrust Banks increased their target price on shares of Syneos Health to $68.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. KeyCorp increased their target price on shares of Syneos Health from $63.00 to $65.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Finally, UBS Group increased their target price on shares of Syneos Health from $53.50 to $57.00 and gave the company a “neutral” rating in a research note on Thursday, August 29th. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $58.63.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Featured Article: Margin

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.